Saudi Arabia Influenza Vaccine Market By Vaccine Type (Inactivated Influenza Vaccine, Live Attenuated Influenza Vaccine), By Distribution Channel (Hospital, Retail Pharmacies, Government Suppliers, Others), By Region, Competition, Forecast & Opportunities, 2021-2031F

Key Insights	Details
Forecast Period	2027-2031
Market Size (2025)	USD 134.56 Million
CAGR (2026-2031)	7.91%
Fastest Growing Segment	Inactivated Influenza Vaccine
Largest Market	Northern & Central
Market Size (2031)	USD 212.46 Million

Market Overview

The Saudi Arabia Influenza Vaccine Market will grow from USD 134.56 Million in 2025 to USD 212.46 Million by 2031 at a 7.91% CAGR. Influenza vaccines are biological preparations designed to confer active acquired immunity against the influenza virus, mitigating the risk and severity of seasonal respiratory illnesses. The Saudi Arabia Influenza Vaccine Market is primarily driven by robust government immunization programs, which include widespread availability and awareness campaigns aimed at vulnerable populations. Additionally, increasing public health awareness regarding infectious diseases and the rising prevalence of influenza cases further support market expansion. The significant annual influx of Hajj and Umrah pilgrims also contributes to a recurring demand for vaccination due to heightened transmission risks.

A notable challenge impeding market expansion is vaccine hesitancy among a segment of the population, often influenced by misinformation. Addressing these perceptions is crucial for achieving higher immunization rates. Despite these challenges, the Ministry of Health reported that, as of January 2025, over 3 million individuals from high-risk groups received the influenza vaccine, demonstrating considerable public health engagement and uptake within the Kingdom.

Key Market Drivers

Government Vaccination Campaigns Drive Market Growth
Robust government vaccination programs significantly drive the Saudi Arabia Influenza Vaccine Market. The Ministry of Health actively implements comprehensive immunization campaigns, leveraging platforms like the Sehhaty application, which as of September 14, 2025, allowed for booking seasonal influenza vaccine appointments. These initiatives are crucial in promoting widespread vaccine uptake, especially among high-risk populations. The emphasis on vaccination is further underscored by the fact that, according to the Ministry of Health, in data from the year prior to September 2025, 96% of patients admitted to intensive care units with influenza had not received the vaccine, highlighting the critical role of these programs in preventing severe outcomes. Such efforts aim to reduce disease burden and associated healthcare costs.

Rising Influenza Incidence Drives Demand and Health Investment
The rising incidence of influenza cases directly fuels demand within the Saudi Arabia Influenza Vaccine Market. Flu seasons often exhibit fluctuating but impactful positivity rates, necessitating timely and effective vaccination strategies. For example, the WHO Eastern Mediterranean Regional bulletin reported that the influenza proportion positive in week 40 of the 2025-2026 season showed a weekly mean positive of 11% compared to 6% in the previous week, indicating an increase in activity. This upward trend directly translates into heightened public and governmental efforts to bolster immunity. The broader commitment to public health is evident in the Saudi Ministry of Finance's official 2025 budget, which allocated SAR 260 billion ($69 billion) for 'Health and Social Development', supporting a robust healthcare infrastructure vital for vaccine distribution and administration.

Download Free Sample Report

Key Market Challenges

Vaccine Hesitancy and Misinformation Limiting Uptake
The challenging factor identified in the overview is vaccine hesitancy among a segment of the population, often influenced by misinformation. This issue directly impedes the growth of the Saudi Arabia Influenza Vaccine Market by limiting the effective reach and uptake of immunization programs. Despite robust government initiatives and awareness campaigns, a portion of the populace remains reluctant to receive the influenza vaccine, leading to suboptimal vaccination rates.

Impact of Hesitancy on Demand and Market Size
This hesitancy translates into reduced demand for vaccines, directly hampering market expansion. For instance, according to the Saudi Pharmaceutical Society, influenza vaccine coverage among the adult population in Saudi Arabia was approximately 32% for the 2024-2025 season, falling short of public health targets. Such lower-than-desired vaccination rates reflect lost opportunities for vaccine sales and administration, thereby constraining the overall market size. Overcoming these perceptions is crucial for increasing the volume of vaccines distributed and administered across the Kingdom.

Key Market Trends

Localization of influenza vaccine manufacturing and national health security
Localization of influenza vaccine manufacturing represents a significant strategic shift within the Saudi Arabia market, aimed at bolstering national health security and reducing reliance on global supply chains. This trend is exemplified by the Memorandum of Understanding signed in October 2025 between CSL Seqirus, Vaccine Industrial Company (VIC), and the Ministry of Health, targeting the local production of cell-based seasonal and pandemic influenza vaccines. This collaboration anticipates supplying locally manufactured cell-based flu vaccines for the 2026-27 season, marking a pivotal step towards self-sufficiency and enhanced pandemic preparedness. This initiative ensures a more stable and responsive vaccine supply, crucial for managing seasonal outbreaks and potential pandemic threats.

Advancement to cell-based platforms and the Sudair facility
Accompanying this localization drive is the advancement in novel vaccine production platforms, particularly the shift towards cell-based technology. These platforms offer enhanced capabilities over traditional egg-based methods, including improved vaccine effectiveness by mitigating mutations that can occur during manufacturing, and enabling faster, more flexible scale-up. The Vaccine Industrial Company's facility in Sudair City, integral to this advancement, is expected to begin coming online from 2028, becoming the first of its kind in Saudi Arabia and the largest in the Middle East for advanced vaccine production. This technological leap promises higher quality, more adaptable influenza vaccines for the Kingdom and the wider region.

Segmental Insights

Inactivated influenza vaccine drives rapid Saudi market growth, propelled by safety, public health initiatives, pilgrimage health protocols, and absence of live-attenuated vaccines.
The Inactivated Influenza Vaccine segment is experiencing the most rapid expansion within the Saudi Arabia Influenza Vaccine Market. This acceleration is primarily driven by its established strong safety profile, rendering it suitable for diverse populations, including vulnerable groups such as the elderly, pregnant women, and immunocompromised individuals. Furthermore, substantial contributions stem from the concerted public health initiatives of the Saudi Ministry of Health, which actively promotes widespread preventative influenza vaccination across the Kingdom, often making it accessible free of charge. The unique health protocols associated with the annual Hajj and Umrah pilgrimages also significantly bolster demand, as vaccination is strongly encouraged or mandated for pilgrims to mitigate disease transmission in crowded environments. Moreover, the current unavailability of live-attenuated influenza vaccines in Saudi Arabia further consolidates the market's focus and growth trajectory on inactivated vaccine formulations.

Regional Insights

Regional Market Leadership Fueled by Infrastructure, Policy Oversight, and Demand
Northern & Central Saudi Arabia leads the influenza vaccine market due to its advanced healthcare infrastructure and significant population density, especially in Riyadh. The presence of government headquarters in Riyadh facilitates the oversight of national vaccination policies and robust immunization logistics networks by the Ministry of Health. Furthermore, the region experiences heightened demand from both residents and travelers, as the Saudi government promotes influenza vaccination within health protocols for Hajj and Umrah pilgrimages. Strong private sector engagement, with numerous private hospitals and clinics, also significantly contributes to vaccine distribution and uptake through corporate wellness programs and individual healthcare services.

Recent Developments

• In October 2025, CSL Seqirus and Vaccine Industrial Company (VIC) signed a Memorandum of Understanding with the Saudi Ministry of Health to localize the manufacturing of cell-based seasonal and pandemic influenza vaccines. This collaboration aims to bolster Saudi Arabia's biotechnology capabilities and pandemic preparedness, with CSL Seqirus supplying its advanced cell-based vaccines. VIC's new facility in Sudair City was designated for local production, intending to establish onshore manufacturing capabilities by 2028. The initiative included plans for pre-pandemic vaccine stockpiles and an advance purchase agreement for the wider community, significantly enhancing national health security.
• In September 2025, the Ministry of Health in Saudi Arabia announced that seasonal influenza vaccine appointments could be conveniently booked through the "Sehhaty" application. This initiative aimed to increase access points for the annual flu immunization campaign, making it easier for residents to schedule their vaccinations. The Ministry highlighted the vaccine's proven effectiveness in reducing infection severity, lowering intensive care admissions, and decreasing influenza-related mortality. This digital enhancement facilitated broader public engagement in preventive healthcare within the Saudi Arabia Influenza Vaccine Market.
• In October 2024, Vaccine Research, Development, and Innovation Co. (Vaccine RDI) entered a Memorandum of Understanding with King Abdulaziz City for Science and Technology (KACST). This strategic partnership aimed to establish a national research laboratory dedicated to vaccine and biopharmaceutical development in Saudi Arabia. The collaboration was a crucial step towards advancing scientific research, technological innovation, and pharmaceutical development within the Kingdom. It specifically focused on promoting technology transfer and localizing pharmaceutical manufacturing to enhance Saudi Arabia's pharmaceutical security, including in the area of influenza vaccines.
• In September 2024, Saudi Arabia's Ministry of Health introduced a pioneering service, offering free home-based seasonal influenza vaccinations via the Sanar application. This groundbreaking initiative marked Saudi Arabia as the first country globally to provide such a service, significantly enhancing vaccine accessibility. The service was strategically designed to reach vulnerable populations, including children, the elderly, individuals with chronic conditions, pregnant women, and healthcare professionals. This strategic expansion of vaccination services aimed to improve public health outcomes by removing barriers to immunization within the Saudi Arabia Influenza Vaccine Market.

Key Market Players

• Sanofi
• GSK
• Pfizer
• Seqirus
• AstraZeneca
• Merck
• Local Vaccine Suppliers
• King Faisal Specialist Hospital
• Ministry of Health Partners
• Al Nahdi Vaccine

By Vaccine Type	By Distribution Channel	By Region
Inactivated Influenza Vaccine Live Attenuated Influenza Vaccine	Hospital Retail Pharmacies Government Suppliers Others	Eastern Northern & Central Western Southern

Report Scope:

In this report, the Saudi Arabia Influenza Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Saudi Arabia Influenza Vaccine Market, By Vaccine Type:

• Inactivated Influenza Vaccine
• Live Attenuated Influenza Vaccine

• Saudi Arabia Influenza Vaccine Market, By Distribution Channel:

• Hospital
• Retail Pharmacies
• Government Suppliers
• Others

• Saudi Arabia Influenza Vaccine Market, By Region:

• Eastern
• Northern & Central
• Western
• Southern